Literature DB >> 1623905

Divergent effects of different enzyme-inducing agents on endogenous and exogenous testosterone.

A Bammel1, K van der Mee, E E Ohnhaus, W Kirch.   

Abstract

The effects of three different enzyme-inducing drugs (antipyrine 1200 mg, phenobarbital 100 mg, rifampicin 600 mg per day for 7 days) on plasma and urinary testosterone concentrations, plasma gonadotropin levels, antipyrine kinetics, and urinary 6 beta-hydroxycortisol excretion were studied in 18 healthy volunteers. Changes in plasma and urinary testosterone concentrations following exogenous testosterone undecanoate (TU) were also investigated. Although both antipyrine and rifampicin increased antipyrine clearance by about 60%, they produced contrary effects on testosterone: antipyrine lowered the total morning plasma testosterone and plasma testosterone AUC following TU, while rifampicin led to increases of about 20% and 78%, respectively. By contrast, phenobarbital did not significantly alter the endogenous and exogenous plasma testosterone concentrations, but it increased the urinary excretion of testosterone by more than 60%. The other two enzyme inducers did not alter this parameter. Gonadotropin levels remained unchanged. The results indicate that different enzyme-inducing agents exert divergent effects on endogenous and exogenous testosterone concentrations and suggest that the effect of enzyme induction on endogenous testosterone depends on the type of microsomal enzyme-inducing drug used rather than on the extent of the induction achieved.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1623905     DOI: 10.1007/bf00265929

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man.

Authors:  E E Ohnhaus; A M Breckenridge; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Integrated concentration and circadian variation of plasma testosterone in normal men.

Authors:  L de Lacerda; A Kowarski; A J Johanson; R Athanasiou; C J Migeon
Journal:  J Clin Endocrinol Metab       Date:  1973-09       Impact factor: 5.958

3.  Determination of 17-hydroxycorticosteroids with p-hydrazinobenzenesulfonic acid-phosphoric acid.

Authors:  A Sanghvi; L Taddeini; C Wight
Journal:  Anal Chem       Date:  1973-01       Impact factor: 6.986

4.  Does rifampicin increase serum levels of testosterone and oestradiol by inducing sex hormone binding globulin capacity?

Authors:  M J Brodie; A R Boobis; M Gill; K Mashiter
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

5.  Essential role of post-heparin lipoprotein lipase activity and of plasma testosterone in coronary artery disease.

Authors:  C Breier; V Mühlberger; H Drexel; M Herold; H J Lisch; E Knapp; H Braunsteiner
Journal:  Lancet       Date:  1985-06-01       Impact factor: 79.321

6.  The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen.

Authors:  A Coert; J Geelen; J de Visser; J van der Vies
Journal:  Acta Endocrinol (Copenh)       Date:  1975-08

7.  Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate.

Authors:  E Nieschlag; J Mauss; A Coert; P Kićović
Journal:  Acta Endocrinol (Copenh)       Date:  1975-06

8.  Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.

Authors:  H M Bolt; M Bolt; H Kappus
Journal:  Acta Endocrinol (Copenh)       Date:  1977-05

9.  A link between liver microsomal enzyme activity and thyroid hormone metabolism in man.

Authors:  E E Ohnhaus; H Studer
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

Review 10.  The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature.

Authors:  D W Nebert; D R Nelson; M J Coon; R W Estabrook; R Feyereisen; Y Fujii-Kuriyama; F J Gonzalez; F P Guengerich; I C Gunsalus; E F Johnson
Journal:  DNA Cell Biol       Date:  1991 Jan-Feb       Impact factor: 3.311

View more
  5 in total

Review 1.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  M T Kinirons; P Crome
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

Review 2.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  SXR, a novel steroid and xenobiotic-sensing nuclear receptor.

Authors:  B Blumberg; W Sabbagh; H Juguilon; J Bolado; C M van Meter; E S Ong; R M Evans
Journal:  Genes Dev       Date:  1998-10-15       Impact factor: 11.361

Review 4.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

Review 5.  Endocrine disrupting contaminants--beyond the dogma.

Authors:  Louis J Guillette
Journal:  Environ Health Perspect       Date:  2006-04       Impact factor: 9.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.